Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 12, Issue 1, 2002, Pages 110-118

  Lundgren, C ^a   Auer, G ^a   Frankendal, B ^a   Moberger, B ^a   Nilsson, B ^a   Nordstrom B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA ploidy; Endometrial carcinoma; Image cytometry; MIB 1; p53; Prognosis

Indexed keywords

CELL NUCLEUS DNA; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DNA CONTENT; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CELL NUCLEUS; CYSTADENOCARCINOMA, SEROUS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 0036193205     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.01079.x     Document Type: Article

References (61)

1. Comparative single cell and flow DNA analysis in aspiration biopsies from breast carcinomas
2. The prognostic significance of DNA measurements in endometrial carcinoma
3. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction
4. MIB-1 in endometrial carcinoma: Prognostic significance with 5-year follow-up
5. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study
6. Mutant p53 protein as a predictor of survival in endometrial carcinoma
7. Methodological aspects on cytochemical DNA assessment of adenocarcinoma of the endometrium by means of image and flow cytometry using conventionally formalin-fixed and paraffin-embedded specimens
8. A prospective comparison of DNA quantitation by image and flow cytometry
9. Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer
10. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
11. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues
12. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form
13. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication
14. Expression of MIB-1 (paraffin ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type
15. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes
16. Flow cytometry in surgical pathlogy and cytology of tumors of the genito-urinary tract
17. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade
18. Proliferation index determined by MIB-1 and recurrence in endometrial cancer
19. Pretreatment assessment of prognostic indicators in endometrial cancer
20. Cancer. p53, guardian of the genome
21. Molecular basis of endometrial cancer
22. Classification and staging of malignant tumors in the female pelvis
23. Stages-1988 revisions. Vulva, ovary, corpus
24. A quantitative cytochemical aspects of a combined Feulgen naphtol-yellow-s staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells
25. Reliability and significance of DNA measurements in interphase nuclei and division figures in histological sections
26. DNA-ploidy and mutant p53 overexpression in primary fallopian tube cancer
27. Pathologic indicators of prognosis in endometrial adenocarcinoma. Selected aspects emphasizing the GOG experience
28. Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma
29. Identification of high-risk groups in endometrial carcinoma stage I-II. A combination of DNA- and steroid receptor-measurements identifies early deaths from the disease
30. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: An important prognostic indicator
31. The prognostic information of DNA ploidy and S-phase fraction may vary with histologic grade in endometrial carcinoma
32. Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: Comparison with other clinical-pathologic parameters
33. Ploidy disturbances as an early indicator of intrinsic malignancy in endometrial carcinoma
34. Evaluation of DNA ploidy in endometrial cancer
35. Carcinoma of the endometrium: Do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications?
36. Prognostic value of DNA ploidy and S-phase fraction in endometrial cancer stage I and II. A prospective 5-year survival study
37. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer
38. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study
39. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma
40. Prognostic characteristics of surgical stage I endometrial adenocarcinoma
41. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma
42. Flow cytometric DNA content analysis of paraffin block embedded endometrial carcinomas
43. Endometrial carcinomas-flow cytometric DNA content and S-phase values
44. Flow cytometry in invasive endometrial carcinoma. Correlations between DNA content S-phase rate and clinical parameters
45. DNA index by image analysis in advanced endometrial carcinoma
46. Monoclonal antibody Ki-67: Its use in histopathology
47. Review: Assessment of cell proliferation in histological material
48. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle
49. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes
50. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma
51. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma
52. Prognostic significance of p53 overexpression in endometrial cancer
53. p53 as a prognostic indicator in endometrial cancer
54. p53 protein over-expression in early stage endometrial cancer
55. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer
56. Clinicopathological characteristics of p53 overexpression in endometrial cancers
57. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus
58. Immunohistochemical analysis of p53 in gynecologic tumors